Gout

Area of Science:

• Rheumatology
• Crystal-induced arthritis

Background:

• Gout is a common inflammatory arthritis caused by monosodium urate crystal deposition.
• Hyperuricemia, elevated serum urate levels, is the primary risk factor for gout development.
• Serum urate homeostasis is regulated by renal and intestinal urate transporters, including GLUT9, URAT1, and ABCG2.

Purpose of the Study:

• To review the pathophysiology of gout, focusing on crystal deposition and inflammatory pathways.
• To discuss the role of urate transporters in hyperuricemia and gout pathogenesis.
• To highlight the efficacy of long-term urate-lowering therapy and supportive care strategies in managing gout.

Main Methods:

• Literature review of gout pathophysiology, risk factors, and treatment strategies.
• Analysis of the mechanisms of monosodium urate crystal deposition and inflammatory responses (e.g., NLRP3 inflammasome, neutrophil extracellular traps).
• Evaluation of the impact of urate-lowering therapies and care models on patient outcomes.

Main Results:

• Monosodium urate crystal deposition triggers NLRP3 inflammasome activation, initiating gout flares.
• Neutrophil extracellular traps are implicated in the resolution phase of gout flares.
• Long-term urate-lowering therapy dissolves crystals, preventing flares, tophi, and improving quality of life.

Conclusions:

• Gout is a chronic, treatable condition requiring long-term management.
• Effective management involves lowering serum urate levels to achieve crystal dissolution.
• Integrated care strategies, such as nurse-led programs, enhance gout management and patient outcomes.